Aetna Better Health® of Virginia Growth Hormone Request Form Fax back to 1-855-799-2553

If the following information is not complete, correct, or legible, the PA process can be delayed. Please use one form per member.

MEMBER INFORMATION	
Last Name:	First Name:
Medicaid ID Number:	Date of Birth:
Conden Decla Decuals	
Gender: Male Female	
PRESCRIBER INFORMATION	
Last Name:	First Name:
NPI Number:	
Phone Number:	Fax Number:
Is the Drug Prescribed by or in Consultation with a Sp	nocialty?
Endocrinologist Nephrologist	rectaity:
DRUG INFORMATION	
Drug Name/Form:	
Strength:	
Quantity per Day:	
All Growth Hormone medications require the submis	ssion of a Clinical Service Authorization
Preferred Medications:	
Genotropin® Norditropin FlexPro®	
Non-Preferred Medications:	
☐ Humatrope® cartridge/vial ☐ Nutropin AQ®	® NuSpin®
☐ Omnitrope® cartridge/vial ☐ Saizen® cartri	idge/vial Serostim® vial
Skytrofa™ Syringe Zomacton® vi	ial Zorbtive® vial
If requesting a non-preferred agent, please documen	it why a preferred agent cannot be used:
(Form continued on next page.)	

Revised: 03/17/2022 | Effective: 07/15/2022

C10539-A 05/2022 Effective: 07/18/2022

Aetna Better Health® of Virginia Growth Hormone Request Form

Me	mber's Last Name:	_	Mem	ber's	s Firs	st Nar	ne:						
CR	ITERIA	_		•	,	•	•	•	'	•			
1.	1. What is the diagnosis? Idiopathic short stature (ISS)												
	Action Required: If YES, please attach document of at least 2 cm/year. Are the growth plates open? Yes No What is the member's current height? Age: Yea		•									·	S
J.	Action Required: Please attach documentation										'	TICTIC	3
DI	AGNOSIS AND MEDICAL INFORMATION												
Co	mplete the Following Section(s) Based on the M	em	ber's I	Diagı	nosis	s. Cor	nplet	e All 1	That A	pply:	•		
Sec	tion A: All Pediatric Indications												
6.	What is the member's pretreatment height and	•											
	Age: Years Months Action Required: Please attach documentation is age at measurement.			_	_			_ inch wing p		tmer	ıt hei	ight d	nd
7.	Which of the following criteria does the membe Greater than or equal to 2.25 standard deviatio Greater than or equal to 2 standard deviatio	itio	ns (SD) bel	ow t	he m	ean f	or age	_		er		
	What is the member's pretreatment growth velocities Greater than 1 standard deviation (SD) below 1 SD below the mean for age and gender Action Required: Please attach documentation is At least 2 heights measured by an endocrino At least 4 heights measured by a primary care rm continued on next page.)	w th	ne mean m the i	<i>medi</i> east	ical r	ecord	show apar	<i>wing e</i> rt (dat	a for a		-	-	·s)
					/	/							

Revised: 03/17/2022 | Effective: 07/15/2022

Mei	mber's Last N	ame:						Men	nber'	's Fir	st Na	me:							
Sect	tion B: Pediat	ric GH D	eficiency	,	<u> </u>	l	_												
9.	Did the mem lab) of at lea Yes Action Requ	nber have st 2 GH s \ No	a GH re	spon on tes	sts LF	Ts?									as de	eterr	ninec	l by	the
10.	Did member Yes Action Requ	☐ No															esult:	s.	
11.	Does the me associated G Yes			ned C	CNS p	atholog	y, h	nistor	y of	crani	al irr	adiat	ion o	or ge	netic	con	ditior	1	
12.	Does the me Yes Action Requ levels below	☐ No ired: <i>If Yi</i>															. and	IGFE	3P-3
13.	Does the me	mber ha	ve 2 or n	nore (docur	mented	pit	uitar	y hor	mon	e de	ficier	ncies	othe	r tha	n GF	1?		
14.	Did the mem	No										neor	natal	hypo	oglyc	emia	?		
Sect	Action Requ tion C: Pediat	_	•					-				c							
	Does the me Creatinin Serum cr	mber ha e clearar	ve any o	f the i mL/r	follov min/1	ving? In 1.73 m2	dic or	ate a Iess		ll the	app	ly: ysis (•		•				
Sect	tion D: Pedia	tric Chro	nic Kidn	ey Di	sease	:													
16.	Is this reques New star				•	_	ion) esta	•	ontir	nuati		GH tinua							
17.	Was GH ther Yes	apy prev	riously ap	prov	ed fo	r this m	em	ber?											
18.	What is the r Action Requ If Restart, n	uired: Ple	ease atta	ch do				om th	 ne те	edica	ıl rec	ord o	f cur	rent	heigl	ht.			
	Is the memb Yes Action Requ at least 2 cm cm continued	☐ No ired: If Y n/year.	ES, pleas	-			-							porti	ng gr	rowth	h velc	ocity	of

Revised: 03/17/2022 | Effective: 07/15/2022

C10539-A 05/2022 Effective: 07/18/2022

IVIE	mber's Last Name:		Men	nber	S FIR	st Na	me:				
Sec	ion E: Adult GH Deficiency			I		<u>I</u>	I		l l		
	Does the member have irreversible hypothalan	nic/	'pituit	ary s	struct	tural	lesion	s or abl	ation?		
	Yes No If YES, no further que	stio	ns.								
21.	Does the member have a defect in GH synthesi	s?									
	Yes No If YES, no further que	stio	ns.								
22.	Did the member have GH deficiency diagnosed Yes No	du	ring c	hildh	nood	?					
22	Does the member have 3 or more pituitary hor	mo	no do	ficio	ncios	.)					
23.	Yes No	1110	ne de	TICIE	licies) :					
24.	Was the member retested for GH deficiency af	ter	an at	least	t 1-m	onth	breal	c in GH t	therapy	·?	
	Yes No										
25.	Which of the following pharmacologic agents w	as u	ısed i	n a G	H sti	mulat	ion te	est to m	easure p	oeak GF	levels?
	Insulin Clonidine Levodopa		Gluc	agon		Ar	ginine	9			
	GH stimulation test not performed	Щ	Othe								
	Action Required: Please attach documentation	sho	owing	the the	resu	lts of	GH st	imulatio	on test.		
	Indicate the peak GH level: ng/mL										
27.	Is the pretreatment IGF-1 level below the labor Yes No	rato	ry's r	ange	of n	orma	1?				
	Action Required: Please attach documentation	fro	m thi	e me	dical	recor	rd sha	wina th	e meml	her's	
	pretreatment IGF-1 level.	j. 0			<i></i>	, , ,	G 5776	villig en	C 111C1112	<i>ye.</i> 5	
Sec	ion F: Short Bowel Syndrome										
28.	Is the member receiving specialized nutritional	sup	port	?							
	Yes No										
29.	Will GH be used in conjunction with optimal ma	ana	geme	ent o	f sho	rt bov	wel sy	ndrome	<u>.</u> ?		
	Yes No										
30.	How many months of GH therapy has the meml	oer	recei	ved?		_ mo	nths	No	t Applic	:able/N	ew Start
Pre	scriber Signature (Required)							Date			
•	ignature, the Physician confirms the above info verifiable by member records.	rma	ation	is ac	curat	:e					
	se include ALL requested information; Incomp mission of documentation does NOT guarantee				ill de	lay th	e PA	process	-		
	Revised: 03/17/202)) I	Fffe	rtive:	. 07/1	15/20	22				

C10539-A 05/2022 Effective: 07/18/2022 Page 4 of 4